33 PEDs cycle progression 2

UNIVERSITY

PEDs
Cycle Progression: 19Nortestosterone
Derivatives


Lesson Overview
Cycle Progression after a Testosterone and DHT
Why 19-Nor as Next Step?
Gynecomastia Primer
Nandrolone Deployment
Trenbolone Deployment
Sample Cycle Design


Cycle Progression
Established testosterone is a base growth anchor in our cycle to
support optimal estrogen and DHT levels.
DHT derivatives (primobolan, masteron, proviron, anavar) have been
deployed a secondary compounds to continue to grow and modulate
side effects
The need for escalating the dosage to continue to grow might be
present and we need a compound to bring about greater anabolism
and limit androgenic effects from higher testosterone. Higher DHT
derivatives are not longer producing the outcomes needed.

The next compound to introduce into the cycle would be a 19-nor
derivative

Why 19-Nortestosterone as a Third
Compound
19-Nortestosteorne is also known as nandrolone and this in fact is naturally occurring in the
body as an intermediate in the aromatization of testosterone
These compounds are more tissue selective than testosterone, however, can interact on
other receptor sites, making them for experience users.
Also 19-Nors are very suppressive and should be reserved for those planning to stay on TRT.
These compounds are progestogenic and can interact with the estrogen receptor
themselves. Interesting fact, Levonorgestrel, a progestin birth control, is analog of
nandrolone.

Removal of the methyl group at position 19 of the steroid backbone significantly reduces the
susceptibility of 19-nor androgens to aromatize as well as undergo 5α-reduction
Some aromatize, some do not.
Some are effected by 5 alpha reductase, some are not.

Will drastically enhance the anabolic to androgenic ratio in your cycle


Gynecomastia Input Understanding

Figure from: Swerdloff 2019


Nandrolone (19-Nortestosterone)
Clinical Application
Came to market in 1962
Application in advanced breast cancer, osteoporosis, anemia, pituitary-deficit growth
hormone, HIV wasting
Still in clinical use today, 100-200mg per week

Properties
Aldosterone Interaction: agonist (increased sodium retention, monitor BP and take
an ARB, remove close to show)
Estrogen Interaction: can interact with the ER, making aromatase inhibitor less
effective in nandrolone induced gyno. Can induce increased aromatase activity
especially in combination with GH/IGF1. Also, greater aromatization to estrone over
estradiol (not enough estrogen for protective health roles, therefore test is our base)
Progesterone Interaction: Can interact with the progesterone receptor producing
estrogen like effects and augment the stimulatory effects of estrogen, also reason
why it is so much more suppressive on the HPTA than other compounds. Promotes
GH production
5-alpha reductase interaction: 5-alpha reduced to a weak androgen
Dihydronandrolone (terrible for libido and erectile function and brain if not enough
DHT present) Likely one driver in “deca dick”.
Cardiovascular: 600mg of nandrolone per week can have greater detriment on HDL
than the equivalent amount of testosterone, 12 weeks post cycle still not fully
restored
Liver: Not c17aa, low liver toxicity; decanoate or phenyl propionate ester for IM
usage
Gynecomastia: Lab work for prolactin, E2, SHBG, IGF1, Testosterone (identify the
source and treat)
ED: Nandrolone suppresses test levels, provides weak estrogen form and weak DHN.
Likely need an increase in testosterone, DHT, or more or less estrogen (check your
labs)


Nandrolone (19-Nortestosterone)
Bodybuilding Application
Offseason:
200-400mg is common dosing. Step Wise approach to dosing based on

need for growth. Advanced users may take this to 600-800mg.
Recommend starting with phenyl propionate ester as dosage changes will
be impact quicker than decanoate ester if problems do arise. If user is
experienced and need for lower shot volume is a factor the decanoate
ester has application.
*Proviron as aid for ED with NPP for lack of DHT and modulate estrogen
for gyno
*Masteron as aid to modulate prolactin and estrogen if this is the issue
*Nolvadex on hand if nandrolone direct action on ER is problematic over
increased aromatization and nonresponsive to AI
*Cabergoline last resort strategy for gyno as Dopamine withdrawal
syndrome is a health risk with this type of product, first line strategy is
lower nandrolone dosage.

Contest Prep:
Compound may be used in initial phase of prep of the need to hold high
levels of muscle development is present
Remove it later stages of prep, 10 weeks out as the aldosterone
interaction can increase water retention, also this may be further
complicated with need to manage estrogen, prolactin and progesterone
activity.
On prep only use the phenyl propionate ester, same offseason dosage
applies


Trenbolone
Clinical Application
SARM not designed for human usage, within drawn from human use in 1990s
Growth promoter i n l ivestock FDA approved 1992, i ncreased feed efficacy. Ca strated steers have move fat mass and lower
wei ght gain. Tren + E2 i nduces greater weight gain l ikely vi a the GH/IGF-1 axis

Cl i nical interest i n enhancing s keletal muscle mass and BMD in individuals with muscle or bone wasting conditions or with
a ndrogen deficiency s yndromes

Properties
Es trogen Interaction: Ca n not aromatize a nd very l ow affinity to the Estrogen receptor i tself. (test base recommended)
Proges terone Interaction: Ca n i nteract with the progesterone receptor (137% that of progesterone i tself) augmenting the
s ti mulatory effects of estrogen, also reason why i t is so much more s uppressive on the HPTA than other compounds. Al so
potential a ctiva tion of BAT and increased night s weats.

Prol a ctin: Ca n ca use direct increase i n prolactin l evels
Gl ucocorticoid interaction: Tren decreases Glucocorticoid binding capacity a nd lower GRs in s keletal muscle and suppress
ACTH s ti mulated cortisol s ynthesis i n the adrenals, significantly reducing protein degradation, excellent during calorie
res tri ction. Potential enhanced glucose uptake.
5-a l pha reductase i nteraction: Not s usceptible to 5alpha reductase vi a the 3-oxotriene s tructure, less androgenic tha n
tes tosterone.
Androgen receptor interaction: 3x i ncreased affinity compared to testosterone, *this does NOT mean i t is 3x s tronger
hypertrophy ga ins.
Ca rdi ovascular: ra ts given 2mg/kg of trenbolone for 6 weeks s howed i mproved lipid profiles (serum TAG 62%, HDL 57%,
LDL 78% reducti ons). Also i ncrease in prostate hyperplasia. 34% decrease in fat mass and 11% i ncrease in l ean mass. No
cha nge in liver markers. 38% reduction i n s erum insulin.
Li polysis: Decreases Visceral fat and whole-body fa t. Decrease l ipid uptake in fat cells a nd i ncrease in Beta-adrenergic
receptors. Pairs well with Beta receptor a gonist.

Li ver: Not c17a a, l ow liver toxi city
Gynecomastia: La b work for prolactin, E2, SHBG, IGF1, Testosterone (identify the source and treat)
ED: Trenbolone s uppresses test a nd DHT levels, l owers estrogen, suppresses LH and FSH (check your labs)
Sl eep: In a surrogate model, melatonin alleviated abnormal sleep behaviors i nduced by trenbolone.
GI di stress: Potential i ncrease in histamine levels i nduce nausea, loss appetite, acid reflux. *l imits offseason application for
thi s reason

Thyroi d a xis: Trenbolone alone decreases T3 and T4 i n ca ttle, but when provi ded estradiol along with tren increase of T4 to
T3 convers ion is present

Brain: Male rats showed elevated Aβ42 levels in the brain within 48 hours of trenbolone injection, in a dosedependent manner, highest does was 5mg/kg (0.85mg/kg human equivalent)


Trenbolone
Bodybuilding Application
Offseason:
Limit application as tren is more advantageous in caloric restriction due to
glucocorticoid reduction and beta 2 upregulation
Trenbolone disadvantageous in the offseason for many due to decreased
appetite and GI issues.
Not human approved; From a safety standpoint has high potential for
neurotoxicity
Testosterone and nandrolone in offseason will be primary growth anchors
Contest Prep:
Large advantage in caloric restriction
100mg is a starting point. 400mg is reaching to the point of diminishing
returns, last 6-12 weeks of contest prep.
*Daily administration of the acetate ester can stabilize serum levels and
lessen side effects.
*pairs very well with growth hormone and clenbuterol
*Masteron use can modulate prolactin increases, *Cabergoline last resort
strategy for gyno as Dopamine withdrawal syndrome is a health risk with
this type of product, first line strategy is lower trenbolone dosage.
*Melatonin use to aid in sleep disruption
*GI distress should be treated by symptom, Zinc Carnosine and digestive
enzymes

Sample Cycle Progression Offseason
*on hand: Nolvadex, Arimidex/Aromasin, Cabergoline
Cycle 4
Test cypionate 400mg/wk
Masteron or Primobolan 400mg/wk
Proviron 25mg/day
Cycle 5
Test cypionate 400mg/wk
Masteron or Primobolan 400mg/wk
Nandrolone Phenyl Propionate 200mg/wk
Proviron 25mg/day
Cycle 6
Test cypionate 400mg/wk
Masteron or Primobolan 500mg/wk
Nandrolone Phenyl Propionate 350mg/wk
Proviron 25mg/day


Sample Cycle Progression Contest Prep
Intermediate
*on hand: Nolvadex, Arimidex/Aromasin, Cabergoline
16 weeks out
Test cypionate 300mg/wk
Primobolan 200mg /wk
Nandrolone Phenyl Propionate 200mg/wk
10 weeks out
Test cypionate 300mg/wk
Masteron 300mg/wk
Trenbolone Acetate 200mg/wk

5 weeks out
Test cypionate 300mg/wk *drop test 2 weeks out if needed for water
retention
Masteron 300mg/wk
Trenbolone Acetate 200mg/wk
Anavar 30mg/day


Summary
Testosterone is our established base growth anchor
A DHT derivative like Proviron, Anavar, Primobolan and/or Masteron
are secondary compounds to deploy.
Our next deployed drug will be a nandrolone derivative. Nandrolone
for offseason usage and Trenbolone reserved in contest prep.
We do have some special phase compounds that can be deployed with
limited usage that we will be reviewing.
Also we are reaching a point in cycle progression that moving into
aggressive dosing likely will require an Aromatase Inhibitor, Selective
Estrogen Receptor Modulator and/or a Dopamine Agonist to advance
more.
Before we deploy these compounds and in higher dosages, I do think
we can get more out our current AAS stack by implementing Growth
Hormone and Insulin, we will cover these items next.


References
Nandrolone
Sirianni R, Capparelli C, Chimento A, Panza S, Catalano S, Lanzino M, Pezzi V, Andò S. Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent
effects on MCF-7 breast cancer cell proliferation. Mol Cell Endocrinol. 2012 Nov 5;363(1-2):100-10. doi: 10.1016/j.mce.2012.08.002. Epub 2012 Aug 10. PMID: 22906881.

Chowdhury P, Mahanta R. Effect of Administration of Nandrolone Decanoate upon Aldosterone Concentration and Serum Na+/K+ Levels in Albino Mice. Cardiovasc Hematol Agents Med
Chem. 2017;14(3):160-166. doi: 10.2174/1871525715666161121152116. PMID: 27875951.Masteron
Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19nortestosterone derivatives. Fertil Steril. 1979 May;31(5):552-61. doi: 10.1016/s0015-0282(16)44003-3. PMID: 446780.

Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Am J
Physiol Endocrinol Metab. 2002 Dec;283(6):E1214-22. doi: 10.1152/ajpendo.00189.2002. Epub 2002 Aug 27. PMID: 12388173.

Bijlsma JW, Duursma SA, Thijssen JH, Huber O. Influence of nandrolondecanoate on the pituitary-gonadal axis in males. Acta Endocrinol (Copenh). 1982 Sep;101(1):108-12. doi:
10.1530/acta.0.1010108. PMID: 6812344.

Bovee TF, Helsdingen RJ, Rietjens IM, Keijer J, Hoogenboom RL. Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent
protein: a comparison of different compounds with both receptor types. J SteroidBiochem Mol Biol. 2004 Jul;91(3):99-109. doi: 10.1016/j.jsbmb.2004.03.118. PMID: 15276617.

Van der Gugten AA. The effect of I-(morpholinomethyl)-4-phtalimido-piperidindione-2,6 and drostanolone propionate on the plasma prolactin concentration of oestrone-treated
orchidectomized R-Amsterdam rats. Eur J Cancer. 1971 Dec;7(6):581-2. doi: 10.1016/0014-2964(71)90066-1. PMID: 5172331.

Trenbolone:
Donner DG, Beck BR, Bulmer AC, Lam AK, Du Toit EF. Improvements in body composition, cardiometabolic risk factors and insulinsensitivity with trenbolone in normogonadic rats.
Steroids. 2015 Feb;94:60-9. doi: 10.1016/j.steroids.2014.12.017. Epub 2014 Dec 30. PMID: 25554582.
Spranger B, Metzler M. Disposition of 17 beta-trenbolone in humans. Journal of Chromatography. 1991 Apr;564(2):485-492.
Ma F, Liu D. 17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.Toxicol Appl Pharmacol. 2015 Jan 1;282(1):68-76.
doi: 10.1016/j.taap.2014.11.007. Epub 2014 Nov 25. PMID: 25461682.

Le Guevel R, Pakdel F. Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods. Hum Reprod. 2001 May;16(5):1030-6.
Bauer ER, Daxenberger A, Petri T, Sauerwein H, Meyer HH. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex
hormone binding globulin and to the bovine progestin receptor. APMIS. 2000 Dec;108(12):838-46.

Thomas KM, Rodway RG. Effects of trenbolone acetate on adrenal function and hepatic enzyme activities in female rats. J Endocrinol. 1983 Jul;98(1):121-7.
Baxa TJ, Hutcheson JP, Miller MF, Brooks JC, Nichols WT, Streeter MN, Yates DA, Johnson BJ. Additive effects of a steroidal implant and zilpaterol hydrochloride on feedlot performance,
carcass characteristics, and skeletal muscle messenger ribonucleic acid abundance in finishing steers. JAnim Sci. 2010 Jan;88(1):330-7.

Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced
androgenic and estrogenic activity. Steroids. 2010 Jun;75(6):377-89. doi: 10.1016/j.steroids.2010.01.019. Epub 2010 Feb 4. PMID: 20138077.

Books:
Llewellyn W. Anabolics. Jupiter, FL: Molecular Nutrition LLC; 2017.
Bond P. Book on Steroids: A complete evidence based reference. PeterBond.org; 2020.

Swerdloff RS, Ng CM. Gynecomastia: Etiology, Diagnosis, and Treatment. [Updated 2019 Jul 7]. In: Feingold KR,Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth
(MA): MDText.com, Inc.; 2000-. Available from: />